Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple mye...

Full description

Bibliographic Details
Main Authors: Conery, Andrew R, Centore, Richard C, Neiss, Adrianne, Keller, Patricia J, Joshi, Shivangi, Spillane, Kerry L, Sandy, Peter, Hatton, Charlie, Pardo, Eneida, Zawadzke, Laura, Bommi-Reddy, Archana, Gascoigne, Karen E, Bryant, Barbara M, Mertz, Jennifer A, Sims, Robert J
Format: Online
Language:English
Published: eLife Sciences Publications, Ltd 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775225/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775225/

Similar Items